Unigene to Present at the Rodman & Renshaw 12th Annual Healthcare Conference

BOONTON, N.J.--(BUSINESS WIRE)-- Unigene Laboratories, Inc. (OTCBB: UGNE), a world leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced it will present at the Rodman & Renshaw 12th Annual Healthcare Conference at 2:50 p.m. Eastern Time on September 14, 2010, in New York, NY. Unigene's President and Chief Executive Officer Ashleigh Palmer will present on the Company's new corporate strategy and business development initiatives to enhance Unigene’s presence in the rapidly growing peptide space. A key component of this strategy is Unigene’s Peptelligence™ platform, representing a distinctive competence originating from the Company’s proprietary expertise and validated suite of patented peptide drug delivery and manufacturing technologies.

The presentation will be webcast. To access the live audio broadcast of the presentation, or the subsequent archived recording, log onto http://www.wsw.com/webcast/rrshq18/ugne. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline, worldwide rights for its calcitonin manufacturing technology to Novartis and worldwide rights (except for China) for its oral calcitonin program to Tarsa Therapeutics, Inc. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin and PTH analogs. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 265-1100 or visit http://www.unigene.com. For information about Fortical, visit http://www.fortical.com.



CONTACT:

Unigene Laboratories, Inc.
William Steinhauer, 973-265-1100
VP of Finance
or
Burns McClellan
Justin Jackson (media)
212-213-0006
[email protected]
or
Michelle Szwarcberg (media)
212-213-0006
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.